资源描述：
《复方醋酸环丙孕酮联合安体舒通治疗不孕的疗效观察》由会员上传分享，免费在线阅读，更多相关内容在行业资料-天天文库。
1、·492·实用妇产科杂志2007年8月第23卷第8期 JournalofPracticalObstetricsandGynecology2007Aug.Vol.23,No.8文章编号:1003-6946(2007)08-492-03复方醋酸环丙孕酮联合安体舒通治疗PCOS不孕的疗效观察翟晓华,黄晓兰(常州市妇幼保健院,江苏常州213003)【摘要】 目的:探讨复方醋酸环丙孕酮(CPA)联合安体舒通治疗PCOS不孕的治疗效果。方法:将96例PCOS不孕患者随机分成两组,实验组给予复方醋酸环丙孕酮1片/d,连续用21日,待撤退性出血第5天开始下一周期治疗,同时给予安体舒通40mg,每日2次。
2、治疗前及治疗3个周期后用化学发光免疫检测FSH、LH、E2、PRL、T。实验组给予治疗3个周期后,对照组在完成各项检查后进行促排卵治疗。结果:实验组治疗后,PCOS临床症状明显改善,LH水平明显降低,LH/FSH恢复正常,T水平明显降低,服药前后比较差异有非常显著性(P<0101)。实验组周期排卵率、单卵泡发育率、妊娠率均显著高于对照组(P<0101)。结论:复方醋酸环丙孕酮联合安体舒通治疗PCOS不孕患者,可改善患者的高雄激素征候群,使多数患者内分泌失调状态调至正常水平,提高促排卵的排卵率及临床妊娠率。【关键词】 多囊卵巢综合征;不孕;复方醋酸环丙孕酮;安体舒通中图分类号:R71117
3、5 文献标识码:AEffectsofDiane235plusSpironolactoneonInfertilePatientswithPolycysticOvarySyndromeZHAIXiaohua,HUANGXiaolan1(MaternityandChildrenHealthHospitalinChangzhouCity,ChangzhouJiangsu213003,China)【Abstract】Objective:Toevaluatethetherapeuticeffectoninfertilepatientsofpolycysticovariansyndrome(PC
4、OS)byDiane235(ethinylestradiolandcyproteroneacetate)plusSpironolactone1Methods:96infertilePCOSpatientsweredividedintotwogroups,studygroupfirstlytakingDiane235cyclicallyplusSpironolactone80mg/dforthreecycles1SerumFSH,LH,E2,PRL,andTweredetectedbeforeandaftertreatment1Thenthestudygroupandthecontrolg
5、roupweretreatedtostimulatedovulationbyCC+HMG1Results:AftertreatedbyDiane235andSpirono2lactone,theclinicalsymptomsofPCOSpatientsinstudygroupimprovedobviously,theirserumLHlevel,LH/FSHratio,andTlevelsdecreasedsignificantly(P<0101)1Comparedtocontrolgroup,ovulatoryratepercycle,singlefollicledevelopmen
6、t,andpregnancyrateofstudygroupwereincreasedsignificantly(P<0101)1Conclusions:TreatmentofDiane235plusSpironolactonecaneffectivelyimprovehyperandrogenisminPCOSpatients,regulatetheirendocrinedisturbance,andfurtherenhancetheirinducedovulatoryrateandclinicalpregnantrate1【Keywords】Polycysticovariansynd
7、rome;Infertility;Ethinylestradiolandcyproteroneacetate;Spironolactone[4]DiRomaE,ParlavecchioE,VettrainoG,etal1CIN:multicentricstudy参考文献oftherapeuticstrategies[J]1MinervaGinecol,2001,53(6):379-3821[5]MurtaEF,SilvaAO,Sil
